Pub Date : 2025-02-01DOI: 10.1016/j.ajt.2024.10.017
Abdullah K. Malik , Samuel J. Tingle , Nicholas Chung , Ruth Owen , Balaji Mahendran , Claire Counter , Sanjay Sinha , Anand Muthasamy , Andrew Sutherland , John Casey , Martin Drage , David van Dellen , Chris J. Callaghan , Doruk Elker , Derek M. Manas , Gavin J. Pettigrew , Colin H. Wilson , Steven A. White , NHSBT Pancreas Advisory Group
{"title":"Erratum to The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation [American Journal of Transplantation 24 (2024) 1247–1256]","authors":"Abdullah K. Malik , Samuel J. Tingle , Nicholas Chung , Ruth Owen , Balaji Mahendran , Claire Counter , Sanjay Sinha , Anand Muthasamy , Andrew Sutherland , John Casey , Martin Drage , David van Dellen , Chris J. Callaghan , Doruk Elker , Derek M. Manas , Gavin J. Pettigrew , Colin H. Wilson , Steven A. White , NHSBT Pancreas Advisory Group","doi":"10.1016/j.ajt.2024.10.017","DOIUrl":"10.1016/j.ajt.2024.10.017","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages 449-450"},"PeriodicalIF":8.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajt.2024.12.005
Lara C. Pullen
{"title":"The HIV Organ Policy Equity Act matures: Breaking down barriers for people with HIV","authors":"Lara C. Pullen","doi":"10.1016/j.ajt.2024.12.005","DOIUrl":"10.1016/j.ajt.2024.12.005","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages 225-227"},"PeriodicalIF":8.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajt.2024.08.027
Verena Broecker , Frederic Toulza , Mats Brännström , Angela Ernst , Candice Roufosse , Marie Carbonnel , Zeinab Alkattan , Johan Mölne
Uterus transplantation is being more widely implemented in clinical practice. Monitoring of rejection is routinely done for cervical biopsies and is dependent on histopathological assessment, as rejections are clinically silent and nonhistological biomarkers are missing. Until this gap is filled, it is important to corroborate the histopathological diagnosis of rejection through independent methods such as gene expression analysis. In this study, we compared our previously published scoring system for grading rejection in uterus transplant cervical biopsies to the gene expression profile in the same biopsy. For this, we used the Banff Human Organ Transplant gene panel to analyze the expression of 788 genes in 75 paraffin-embedded transplant cervical biopsies with a spectrum of histologic findings, as well as in 24 cervical biopsies from healthy controls. We found that gene expression in borderline changes did not differ from normal transplants, whereas the genes with increased expression in mild rejections overlapped with previously published rejection-associated transcripts. Moderate/severe rejection samples showed a gene expression pattern characterized by a mixture of rejection-associated and tissue injury–associated genes and a decrease in epithelial transcripts. In summary, our findings support our proposed scoring system for rejection but argue against the treatment of borderline changes.
{"title":"Transcript analysis of uterus transplant cervical biopsies using the Banff Human Organ Transplant panel","authors":"Verena Broecker , Frederic Toulza , Mats Brännström , Angela Ernst , Candice Roufosse , Marie Carbonnel , Zeinab Alkattan , Johan Mölne","doi":"10.1016/j.ajt.2024.08.027","DOIUrl":"10.1016/j.ajt.2024.08.027","url":null,"abstract":"<div><div>Uterus transplantation is being more widely implemented in clinical practice. Monitoring of rejection is routinely done for cervical biopsies and is dependent on histopathological assessment, as rejections are clinically silent and nonhistological biomarkers are missing. Until this gap is filled, it is important to corroborate the histopathological diagnosis of rejection through independent methods such as gene expression analysis. In this study, we compared our previously published scoring system for grading rejection in uterus transplant cervical biopsies to the gene expression profile in the same biopsy. For this, we used the Banff Human Organ Transplant gene panel to analyze the expression of 788 genes in 75 paraffin-embedded transplant cervical biopsies with a spectrum of histologic findings, as well as in 24 cervical biopsies from healthy controls. We found that gene expression in borderline changes did not differ from normal transplants, whereas the genes with increased expression in mild rejections overlapped with previously published rejection-associated transcripts. Moderate/severe rejection samples showed a gene expression pattern characterized by a mixture of rejection-associated and tissue injury–associated genes and a decrease in epithelial transcripts. In summary, our findings support our proposed scoring system for rejection but argue against the treatment of borderline changes.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages 329-342"},"PeriodicalIF":8.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142102459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajt.2024.09.017
Timothy L. Pruett , Susan M. Wolf , Claire Colby McVan , Peter Lyon , Alexander M. Capron , James F. Childress , Barbara J. Evans , Erik B. Finger , Insoo Hyun , Rosario Isasi , Gary E. Marchant , Andrew D. Maynard , Kenneth A. Oye , Mehmet Toner , Korkut Uygun , John C. Bischof
Time limits on organ viability from retrieval to implantation shape the US system for human organ transplantation. Preclinical research has demonstrated that emerging biopreservation technologies can prolong organ viability, perhaps indefinitely. These technologies could transform transplantation into a scheduled procedure without geographic or time constraints, permitting organ assessment and potential preconditioning of the recipients. However, the safety and efficacy of advanced biopreservation with prolonged storage of vascularized organs followed by reanimation will require new regulatory oversight, as clinicians and transplant centers are not trained in the engineering techniques involved or equipped to assess the manipulated organs. Although the Food and Drug Administration is best situated to provide that process oversight, the agency has until now declined to oversee organ quality and has excluded vascularized organs from the oversight framework of human cells, tissues, and cellular-based and tissue-based products. Integration of advanced biopreservation technologies will require new facilities for organ preservation, storage, and reanimation plus ethical guidance on immediate organ use versus preservation, national allocation, and governance of centralized organ banks. Realization of the long-term benefit of advanced biopreservation requires anticipation of the necessary legal and ethical oversight tools and that process should begin now.
{"title":"Governing new technologies that stop biological time: Preparing for prolonged biopreservation of human organs in transplantation","authors":"Timothy L. Pruett , Susan M. Wolf , Claire Colby McVan , Peter Lyon , Alexander M. Capron , James F. Childress , Barbara J. Evans , Erik B. Finger , Insoo Hyun , Rosario Isasi , Gary E. Marchant , Andrew D. Maynard , Kenneth A. Oye , Mehmet Toner , Korkut Uygun , John C. Bischof","doi":"10.1016/j.ajt.2024.09.017","DOIUrl":"10.1016/j.ajt.2024.09.017","url":null,"abstract":"<div><div>Time limits on organ viability from retrieval to implantation shape the US system for human organ transplantation. Preclinical research has demonstrated that emerging biopreservation technologies can prolong organ viability, perhaps indefinitely. These technologies could transform transplantation into a scheduled procedure without geographic or time constraints, permitting organ assessment and potential preconditioning of the recipients. However, the safety and efficacy of advanced biopreservation with prolonged storage of vascularized organs followed by reanimation will require new regulatory oversight, as clinicians and transplant centers are not trained in the engineering techniques involved or equipped to assess the manipulated organs. Although the Food and Drug Administration is best situated to provide that process oversight, the agency has until now declined to oversee organ quality and has excluded vascularized organs from the oversight framework of human cells, tissues, and cellular-based and tissue-based products. Integration of advanced biopreservation technologies will require new facilities for organ preservation, storage, and reanimation plus ethical guidance on immediate organ use versus preservation, national allocation, and governance of centralized organ banks. Realization of the long-term benefit of advanced biopreservation requires anticipation of the necessary legal and ethical oversight tools and that process should begin now.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages 269-276"},"PeriodicalIF":8.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajt.2024.09.005
Vincenzo Villani, Jeffrey H. Fair, Rupak D. Kulkarni
{"title":"An uncommon complication after living donor nephrectomy","authors":"Vincenzo Villani, Jeffrey H. Fair, Rupak D. Kulkarni","doi":"10.1016/j.ajt.2024.09.005","DOIUrl":"10.1016/j.ajt.2024.09.005","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages 444-446"},"PeriodicalIF":8.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143050955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-01DOI: 10.1016/j.ajt.2025.01.021
Raja Kandaswamy , Peter G. Stock , Jonathan M. Miller , Dzhuliyana Handarova , Ajay K. Israni , Jon J. Snyder
The overall number of pancreas transplants in the United States remained relatively unchanged in 2023 at 915 transplants, compared with 918 transplants in 2022. The number of pancreas-after-kidney transplants continued to decline and reached the lowest level in the past decade: 36 transplants in 2023. The proportion of pancreas recipients with type 2 diabetes increased to 25.4% in 2023 from 22.5% in 2022, comparable to the proportion of candidates with type 2 diabetes on the waiting list increasing to 25.2% in 2023 compared with 23.4% in 2022. The number of adult additions to the pancreas waiting list increased in 2023 to 1,876 compared with 1,736 in 2022. The proportion of candidates on the waiting list who are older, obese, or have type 2 diabetes has been increasing. The number of pancreas donors decreased in 2023 compared with 2022; however, the nonuse rate also decreased during the same period. The distribution of volume across transplant centers was relatively unchanged in 2023, with only 5% of centers performing more than 30 transplants a year. Outcomes of pancreas transplants were relatively stable from 2020 to 2022, with 1-year pancreas graft survival rates in adults of 90.8% in simultaneous pancreas-kidney transplant, 87.5% in pancreas transplant alone, and 84.4% in pancreas-after-kidney transplant for transplants performed in 2022. Kidney 1-year graft survival in simultaneous pancreas-kidney transplant was excellent at 96.2% for transplants in 2022.
{"title":"OPTN/SRTR 2023 Annual Data Report: Pancreas","authors":"Raja Kandaswamy , Peter G. Stock , Jonathan M. Miller , Dzhuliyana Handarova , Ajay K. Israni , Jon J. Snyder","doi":"10.1016/j.ajt.2025.01.021","DOIUrl":"10.1016/j.ajt.2025.01.021","url":null,"abstract":"<div><div>The overall number of pancreas transplants in the United States remained relatively unchanged in 2023 at 915 transplants, compared with 918 transplants in 2022. The number of pancreas-after-kidney transplants continued to decline and reached the lowest level in the past decade: 36 transplants in 2023. The proportion of pancreas recipients with type 2 diabetes increased to 25.4% in 2023 from 22.5% in 2022, comparable to the proportion of candidates with type 2 diabetes on the waiting list increasing to 25.2% in 2023 compared with 23.4% in 2022. The number of adult additions to the pancreas waiting list increased in 2023 to 1,876 compared with 1,736 in 2022. The proportion of candidates on the waiting list who are older, obese, or have type 2 diabetes has been increasing. The number of pancreas donors decreased in 2023 compared with 2022; however, the nonuse rate also decreased during the same period. The distribution of volume across transplant centers was relatively unchanged in 2023, with only 5% of centers performing more than 30 transplants a year. Outcomes of pancreas transplants were relatively stable from 2020 to 2022, with 1-year pancreas graft survival rates in adults of 90.8% in simultaneous pancreas-kidney transplant, 87.5% in pancreas transplant alone, and 84.4% in pancreas-after-kidney transplant for transplants performed in 2022. Kidney 1-year graft survival in simultaneous pancreas-kidney transplant was excellent at 96.2% for transplants in 2022.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages S138-S192"},"PeriodicalIF":8.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-31DOI: 10.1016/j.ajt.2025.01.042
Stalin Canizares, David D Lee
{"title":"Response to \"The under-reporting of liver machine perfusion in US national data\".","authors":"Stalin Canizares, David D Lee","doi":"10.1016/j.ajt.2025.01.042","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.01.042","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143077991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-31DOI: 10.1016/j.ajt.2025.01.036
Hanne Beeckmans, Pieterjan Kerckhof, Nilufer Acet Öztürk, Andrea Zajacova, Jan Van Slambrouck, Saskia Bos, Marie Vermant, Lyne O Van Dieren, Tessa Goeminne, Christelle Vandervelde, Josephine Bardyn, Elisabeth Willems, Sam Lauriers, Marius Brusselmans, Leen Van Langenhoven, Marie Paule Emonds, Steffi De Pelsmaeker, Johan Kerkhofs, Laurens De Sadeleer, Laurent Godinas, Lieven J Dupont, Dirk E Van Raemdonck, Laurens J Ceulemans, Bart M Vanaudenaerde, Robin Vos
Risk factors for restrictive allograft syndrome (RAS), a severe phenotype of chronic lung allograft dysfunction (CLAD) after lung transplantation, are currently not well known. In this retrospective nested case-control-study, we analyzed 69 patients with RAS and 69 matched non-CLAD controls to identify clinical risk factors for RAS. Patients with RAS demonstrated overall higher blood eosinophils (P = .02), increased bronchoalveolar eosinophils (P < .001) and lymphocytes (P = .03), and higher incidence of infections, particularly Pseudomonas species infection (P = .003), invasive fungal disease (P < .001, mainly due to Aspergillus species), SARS-CoV-2 (P < .001), and cytomegalovirus infection (P = .04), compared with non-CLAD controls. Antihuman leukocyte antigen (anti-HLA) antibodies, especially persistent donor-specific antibodies (P < 0.001), specifically targeting HLA-DQ and HLA-DR loci, and antibody-mediated rejection (P < .001), were strongly associated with later RAS. Histopathologic lung injury patterns on transbronchial biopsy (P < .001), and persistent chest computed tomography opacities in absence of pulmonary dysfunction (P < .001) were identified as early indicators of later RAS. Proactive detection and management of these risk factors could help mitigate future decline in allograft function and reduce progression to clinical RAS. Future studies should explore early treatment strategies targeting these modifiable factors to preserve allograft function and improve long-term outcomes for lung transplant recipients.
{"title":"Clinical predictors for restrictive allograft syndrome: a nested case-control study.","authors":"Hanne Beeckmans, Pieterjan Kerckhof, Nilufer Acet Öztürk, Andrea Zajacova, Jan Van Slambrouck, Saskia Bos, Marie Vermant, Lyne O Van Dieren, Tessa Goeminne, Christelle Vandervelde, Josephine Bardyn, Elisabeth Willems, Sam Lauriers, Marius Brusselmans, Leen Van Langenhoven, Marie Paule Emonds, Steffi De Pelsmaeker, Johan Kerkhofs, Laurens De Sadeleer, Laurent Godinas, Lieven J Dupont, Dirk E Van Raemdonck, Laurens J Ceulemans, Bart M Vanaudenaerde, Robin Vos","doi":"10.1016/j.ajt.2025.01.036","DOIUrl":"10.1016/j.ajt.2025.01.036","url":null,"abstract":"<p><p>Risk factors for restrictive allograft syndrome (RAS), a severe phenotype of chronic lung allograft dysfunction (CLAD) after lung transplantation, are currently not well known. In this retrospective nested case-control-study, we analyzed 69 patients with RAS and 69 matched non-CLAD controls to identify clinical risk factors for RAS. Patients with RAS demonstrated overall higher blood eosinophils (P = .02), increased bronchoalveolar eosinophils (P < .001) and lymphocytes (P = .03), and higher incidence of infections, particularly Pseudomonas species infection (P = .003), invasive fungal disease (P < .001, mainly due to Aspergillus species), SARS-CoV-2 (P < .001), and cytomegalovirus infection (P = .04), compared with non-CLAD controls. Antihuman leukocyte antigen (anti-HLA) antibodies, especially persistent donor-specific antibodies (P < 0.001), specifically targeting HLA-DQ and HLA-DR loci, and antibody-mediated rejection (P < .001), were strongly associated with later RAS. Histopathologic lung injury patterns on transbronchial biopsy (P < .001), and persistent chest computed tomography opacities in absence of pulmonary dysfunction (P < .001) were identified as early indicators of later RAS. Proactive detection and management of these risk factors could help mitigate future decline in allograft function and reduce progression to clinical RAS. Future studies should explore early treatment strategies targeting these modifiable factors to preserve allograft function and improve long-term outcomes for lung transplant recipients.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143072934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-31DOI: 10.1016/j.ajt.2025.01.040
Ellen Green, E Glenn Dutcher, Jesse D Schold, Darren Stewart
Despite the high demand, over 7,500 recovered kidneys annually go unused, with transplant centers showing significant variation in their offer acceptance practices. However, it remains unclear how much of this variation occurs between individual clinicians within the same center and its impact on allocation efficiency and equity. This study quantified the variability in kidney offer acceptance decisions attributable to clinicians versus enters and examined the role of donor quality in acceptance decisions. We analyzed national transplant registry data (Jan. 2016-Dec. 2020) linked to on-call records from 15 transplant centers, creating a clinician-level dataset with 344,678 deceased donor kidney offers. The primary outcome was the variability in offer acceptance attributable to clinicians versus centers, quantified via hierarchical, mixed effects logistic regression models. To complement KDPI as a measure of donor quality, we incorporated Expected Acceptance Probability (EAP), which adjusts for a broader set of donor characteristics and also recipient factors. Both center-level (0.35, 95% CI: 0.15-0.79) and clinician-level variance (0.10, 95% CI: 0.06-0.18) were significant, with heterogeneity in the KDPI-acceptance association among clinicians. These results underscore the need for further research into the mechanisms driving the clinician-level variation and its implications for organ allocation efficacy, equity, and patient outcomes.
{"title":"The Dynamics of Deceased Donor Kidney Transplant Decision-Making: Insights from Studying Individual Clinicians' Offer Decisions.","authors":"Ellen Green, E Glenn Dutcher, Jesse D Schold, Darren Stewart","doi":"10.1016/j.ajt.2025.01.040","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.01.040","url":null,"abstract":"<p><p>Despite the high demand, over 7,500 recovered kidneys annually go unused, with transplant centers showing significant variation in their offer acceptance practices. However, it remains unclear how much of this variation occurs between individual clinicians within the same center and its impact on allocation efficiency and equity. This study quantified the variability in kidney offer acceptance decisions attributable to clinicians versus enters and examined the role of donor quality in acceptance decisions. We analyzed national transplant registry data (Jan. 2016-Dec. 2020) linked to on-call records from 15 transplant centers, creating a clinician-level dataset with 344,678 deceased donor kidney offers. The primary outcome was the variability in offer acceptance attributable to clinicians versus centers, quantified via hierarchical, mixed effects logistic regression models. To complement KDPI as a measure of donor quality, we incorporated Expected Acceptance Probability (EAP), which adjusts for a broader set of donor characteristics and also recipient factors. Both center-level (0.35, 95% CI: 0.15-0.79) and clinician-level variance (0.10, 95% CI: 0.06-0.18) were significant, with heterogeneity in the KDPI-acceptance association among clinicians. These results underscore the need for further research into the mechanisms driving the clinician-level variation and its implications for organ allocation efficacy, equity, and patient outcomes.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号